COVID 19NCT04354753
AiM COVID for Covid 19 Tracking and Prediction
An observational study of COVID 19, run by Aarogyam UK at 1 site in United Kingdom.
Trial summary
University of Warwick (Coventry, UK) and NTUU "Igor Sikorsky" Kyiv Polytechnic Institute (Kyiv, Ukraine), together with ClickMedix LLC, have developed an app and a chatbot "AiM COVID" for efficient monitoring and mitigation of COVID-19. These products are available for free download on computers and mobile phones. Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- COVID 19
- How many people
- 80 participants
- Where
- 1 siteUnited Kingdom
- Study dates
- 28 Mar 2020to 17 Apr 2020
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: Participants who registered or used any community support services in Leicester
Who may be able to join
- Participants 18 and above
- living in UK
- reported with or without symptoms from February 28 to March 28 with community support groups
Who cannot join
- below 18 years old
Trial locations and contacts
1 site in 1 country.
About this study
University of Warwick (Coventry, UK) and NTUU "Igor Sikorsky" Kyiv Polytechnic Institute (Kyiv, Ukraine), together with ClickMedix LLC, have developed an app and a chatbot "AiM COVID" for efficient monitoring and mitigation of COVID-19. These products are available for free download on computers and mobile phones. These can be used by a wide range of users from various sectors - patients and people living with them, doctors, nurses, specialists, community health workers, hospitals, clinics, hospital IT staff, MHFA, and insurance companies.
- Conditions
- COVID 19
- Being tested
- No Intervention
- Medical subject headings
- COVID-19
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
No InterventionOther
No intervention
What is being measured
The primary outcome is the main question the study is designed to answer.
Physical symptoms
Self reported physical symptoms
Measured: 1day
Contact History
Contact with suspected, confirmed or ill person
Measured: 14 days
Travel History
Travel to or from overseas
Measured: 14 days
Secondary outcomes (14)
Fever
Self reported body temperature
Measured: 1 day
Headache
Self reported headache using yes/no
Measured: 1 day
Soar Throat
Self reported soar throat using yes/no
Measured: 1 day
Runny nose
Self reported runny nose using yes/no
Measured: 1 day
Cough
Self reported cough using yes/no
Measured: 1 day
Shortness of breath
Self reported shortness of breath symptoms using yes/no
Measured: 1 day
Nausea
Self reported nausea using yes/no
Measured: 1 day
Vomiting
Self reported vomiting using yes/no
Measured: 1 day
Muscle pain
Self reported muscle pain using yes/no
Measured: 1 day
Joint pain
Self reported joint pain using yes/no
Measured: 1 day
Diarrhoea
Self reported Diarrhoea using yes/no
Measured: 1 day
Other
Self reported other symptoms using yes/no
Measured: 1 day
Hospitalisation history
Self reported hospitalisation using yes/no
Measured: 1 day
Co-morbid conditions
Self reported co-morbid conditions using checked box
Measured: 1 day
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted21 Apr 2020
- Study start28 Mar 2020
- Primary completion14 Apr 2020
- Study completion17 Apr 2020
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for COVID 19Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Retrospective
- Enrolment
- 80 participants (actual)
Sponsor and investigators
- Lead sponsor
- Aarogyam UK
- Sponsor type
- University, hospital or other
- Collaborators
- University of Warwick, Igor Sikorsky Kyiv Polytechnic Institute, ClickMedix LLC
- Responsible party
- Sponsor
- Investigators
- Vishwesh Kulkarni, Principal investigator, University of Warwick
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04354753
- Sponsor's protocol ID
- AU12
- Status last verified
- Apr 2020
- First submitted
- 17 Apr 2020
- Last updated
- 21 Apr 2020
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 21 Apr 2020. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- AiM COVID for Covid 19 Tracking and Prediction
- ClinicalTrials.gov ID
- NCT04354753
- Acronym / sponsor ID
- AU12
- Conditions
- COVID 19
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 80 participants (actual)
- Lead sponsor
- Aarogyam UKUniversity, hospital or other
- Collaborators
- University of Warwick, Igor Sikorsky Kyiv Polytechnic Institute, ClickMedix LLC
- Study start
- 28 Mar 2020 (actual)
- Primary completion
- 14 Apr 2020 (actual)
- Study completion
- 17 Apr 2020 (actual)
- First posted
- 21 Apr 2020 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
University of Warwick (Coventry, UK) and NTUU "Igor Sikorsky" Kyiv Polytechnic Institute (Kyiv, Ukraine), together with ClickMedix LLC, have developed an app and a chatbot "AiM COVID" for efficient monitoring and mitigation of COVID-19. These products are available for free download on computers and mobile phones. These can be used by a wide range of users from various sectors - patients and people living with them, doctors, nurses, specialists, community health workers, hospitals, clinics, hospital IT staff, MHFA, and insurance companies.
Study design
- Observational model
- Case only
- Time perspective
- Retrospective
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- Participants who registered or used any community support services in Leicester
Key inclusion criteria (3 listed)
- Participants 18 and above
- living in UK
- reported with or without symptoms from February 28 to March 28 with community support groups
Key exclusion criteria (1 listed)
- below 18 years old
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| No InterventionNo intervention | Other | – |
Primary outcome
Physical symptoms
Time frame: 1day
Self reported physical symptoms
Contact History
Time frame: 14 days
Contact with suspected, confirmed or ill person
Travel History
Time frame: 14 days
Travel to or from overseas
14 secondary outcomes
Fever
Time frame: 1 day
Headache
Time frame: 1 day
Soar Throat
Time frame: 1 day
Runny nose
Time frame: 1 day
Cough
Time frame: 1 day
Shortness of breath
Time frame: 1 day
Nausea
Time frame: 1 day
Vomiting
Time frame: 1 day
Muscle pain
Time frame: 1 day
Joint pain
Time frame: 1 day
Diarrhoea
Time frame: 1 day
Other
Time frame: 1 day
Hospitalisation history
Time frame: 1 day
Co-morbid conditions
Time frame: 1 day
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 21 Apr 2020.
- Individual participant dataSharing planned: Undecided
Related trials for COVID 19
Recruiting
Whole-body Cryotherapy in Those With Chronic Fatigue: A Feasibility Study
ME/CFS, Fibromyalgia (FM)
Not yet recruitingPhase 1
Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)
Post-Acute COVID-19 Syndrome
Active, not recruiting
Working Towards Empowered Community-driven Approaches to Increase Vaccination and Preventive Care Engagement
COVID-19
Active, not recruitingObservational study
Epigenetic Changes in Long COVID Patients
Long COVID-19 Syndrome, Long COVID Symptoms
RecruitingPhase 3
Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia
Respiratory Tract Diseases, Influenza (Pandemic)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Vishwesh Kulkarni principal investigator
University of Warwick
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of COVID 19, run by Aarogyam UK at 1 site in United Kingdom.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 21 Apr 2020. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Physical symptoms (time frame: 1day). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Apr 2020.